Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?

被引：8
作者：
Ramirez, Celeo [1 ,2 ]
Herrera-Paz, Edwin F. [1 ,3 ]
Peralta, Guimel [1 ,4 ]
Rodriguez, Gaspar [1 ,5 ]
Duron, Reyna M. [1 ,4 ]
机构：
[1] Consorcio Invest COVID Honduras, Tegucigalpa 11101, Honduras
[2] Hosp Valle, Bulevar Norte,8 Calle NE, San Pedro Sula 21101, Honduras
[3] Univ Catolica Honduras, Escuela Med, Campus San Pedro & San Pablo, San Pedro Sula 21102, Honduras
[4] Univ Tecnol Centroamer UNITEC, Fac Ciencias Salud, Tegucigalpa 11101, Honduras
[5] Hosp Especialidades Ctr Med La Raza, Inst Hondureno Seguro Social, Tegucigalpa, Honduras
来源：
ECLINICALMEDICINE | 2021年 / 32卷
关键词：
D O I：
10.1016/j.eclinm.2021.100744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 8 条
  • [1] The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro
    Caly, Leon
    Druce, Julian D.
    Catton, Mike G.
    Jans, David A.
    Wagstaff, Kylie M.
    [J]. ANTIVIRAL RESEARCH, 2020, 178
  • [2] The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial
    Chaccour, Carlos
    Casellas, Aina
    Blanco-Di Matteo, Andres
    Pineda, Inigo
    Fernandez-Montero, Alejandro
    Ruiz-Castillo, Paula
    Richardson, Mary-Ann
    Rodriguez-Mateos, Mariano
    Jordan-Iborra, Carlota
    Brew, Joe
    Carmona-Torre, Francisco
    Giraldez, Miriam
    Laso, Ester
    Gabaldon-Figueira, Juan C.
    Dobano, Carlota
    Moncunill, Gemma
    Yuste, Jose R.
    Del Pozo, Jose L.
    Rabinovich, N. Regina
    Schoening, Verena
    Hammann, Felix
    Reina, Gabriel
    Sadaba, Belen
    Fernandez-Alonso, Mirian
    [J]. ECLINICALMEDICINE, 2021, 32
  • [3] Feasibility of Onchocerciasis Elimination with Ivermectin Treatment in Endemic Foci in Africa: First Evidence from Studies in Mali and Senegal
    Diawara, Lamine
    Traore, Mamadou O.
    Badji, Alioune
    Bissan, Yiriba
    Doumbia, Konimba
    Goita, Soula F.
    Konate, Lassana
    Mounkoro, Kalifa
    Sarr, Moussa D.
    Seck, Amadou F.
    Toe, Laurent
    Touree, Seyni
    Remme, Jan H. F.
    [J]. PLOS NEGLECTED TROPICAL DISEASES, 2009, 3 (07):
  • [4] Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection
    Gardon, J
    GardonWendel, N
    DemangaNgangue, D
    Kamgno, J
    Chippaux, JP
    Boussinesq, M
    [J]. LANCET, 1997, 350 (9070) : 18 - 22
  • [5] Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects
    Guzzo, CA
    Furtek, CI
    Porras, AG
    Chen, C
    Tipping, R
    Clineschmidt, CM
    Sciberras, DG
    Hsieh, JYK
    Lasseter, KC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (10) : 1122 - 1133
  • [6] A Large, Simple Trial Leading to Complex Questions
    Harrington, David P.
    Baden, Lindsey R.
    Hogan, Joseph W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (06) : 576 - 577
  • [7] Lessons from New Zealand's COVID-19 outbreak response
    Robert, Alexis
    [J]. LANCET PUBLIC HEALTH, 2020, 5 (11) : E569 - E570
  • [8] First case of ivermectin-induced severe hepatitis
    Veit, Olivia
    Beck, Bernhard
    Steuerwald, Michael
    Hatz, Christoph
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 2006, 100 (08) : 795 - 797
1